Pharvaris N.V. filings document foreign private issuer disclosures for a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists. Form 6-K reports furnish financial results, business updates, investor presentations, clinical-study updates, annual general meeting voting results and materials incorporated by reference into Form F-3 and Form S-8 registration statements.
The filing record also covers capital-structure activity involving ordinary shares and pre-funded warrants, registration rights agreements, underwriting documents, share-based compensation and governance matters. These disclosures frame Pharvaris' development-stage operating expenses, financing activity, shareholder approvals and formal reporting obligations as a Nasdaq-listed foreign private issuer.
PHVS files a Form 144 reporting proposed sale of 15,000 shares of Common Stock. The filing states the shares relate to an exercise of stock options and are to be sold for cash on 06/25/2026. The excerpt also lists prior 10b5-1 sales in April–June 2026 totaling multiple transactions, including 14,166 and 15,000 share sales on 05/01/2026 and 04/30/2026, respectively.
PHVS filed a Form 144 reporting sales of Common Stock under prearranged 10b5-1 plans. The filing lists broker-dealer Morgan Stanley Smith Barney LLC and shows multiple 10b5-1 sales by Anne Simonne J. Lesage and Graymatters Consulting on 04/22/2026, 04/23/2026, 04/29/2026, and 04/30/2026
Examples shown include 21,700 shares sold by Lesage on 04/30/2026 for $656,550.86 and 19,200 shares sold by Graymatters Consulting on 04/30/2026 for $580,909.44. Shares outstanding are listed as 65,210,590 shares as of 06/25/2026.
PHVS filed a Form 144 reporting a proposed sale of 2,300 shares of Common Stock in connection with the exercise of stock options scheduled for 06/25/2026. The filing lists prior 10b5-1 plan sales in April 2026 by two related holders, including multiple trades on 04/30/2026 and earlier dates.
The notice names a broker-dealer, Morgan Stanley Smith Barney LLC, and records cash settlement. The filing is administrative disclosure of an intended resale under Rule 144 and describes recent 10b5-1 sales by Anne Simonne J. Lesage and Graymatters Consulting.
PHVS filed a Form 144 reporting proposed/resale sales of Common Stock by a selling holder. The excerpt lists multiple 10b5-1 programmed sales by Hans H. Schikan totaling reported trades on 04/22/2026, 04/23/2026, 04/29/2026, and 04/30/2026.
The transactions include 7,000 shares on 04/22/2026 and 29,070 shares on 04/30/2026, with gross proceeds shown in the excerpt for each trade. The filing also references 2,400 Founders Shares in the securities table.
Pharvaris N.V.’s Chief Medical Officer Lu Peng reported a small, scheduled option exercise and share sale. On June 18, 2026, Peng exercised stock options to acquire 300 shares of common stock at $2.59 per share and sold 300 common shares at $34.00 per share in an open-market transaction.
The filing states this was done under a Rule 10b5-1 trading plan. After these transactions, Peng directly holds 65,631 common shares and 205,008 stock options with a $2.59 exercise price expiring on February 3, 2030, indicating the sale involved only a small portion of the overall position.
PHVS-related filing: A Form 144 reports the proposed sale following an exercise of 300 common shares on 06/18/2026. The filing also lists recent Rule 10b5-1 sales in Apr–May 2026, with individual transactions such as 14,166 shares on 05/01/2026.
Pharvaris N.V. director and Chief Executive Officer Berndt Modig reported small open-market sales of company common stock. On June 15, 2026, he sold a total of 2,291 shares in two transactions at weighted average prices of about $31.05 and $31.46 per share, executed under a Rule 10b5-1 trading plan. The filing notes that the sold shares included stock previously acquired through vesting of restricted stock units. Following these sales, Modig holds 135,209 shares directly and 950,000 shares indirectly through Schoodic Management BV, an entity he controls.
Pharvaris N.V. Chief Medical Officer Lu Peng had 117 shares of Common Stock withheld on June 12, 2026 to cover tax obligations from vesting restricted stock units. The shares were valued at $32.20 each based on fair market value, and Peng now directly holds 65,631 shares.
Pharvaris N.V. Chief Medical Officer Lu Peng reported a small share disposition tied to equity compensation. On the vesting of restricted stock units on June 11, 2026, 109 shares of common stock were withheld to cover tax withholding obligations at a fair market value of $31.51 per share. After this tax-withholding event, Lu Peng directly owns 65,748 shares of Pharvaris common stock, so the filing reflects routine administration of stock-based compensation rather than an open-market trade.
PHVS notice: a brokered Rule 144 submission lists 2,291 Restricted Stock Units dated 06/11/2026 proposed for sale and records recent 10b5-1 sales by Berndt B.A.E. Modig on 05/15/2026, 04/16/2026, and 04/08/2026 with proceeds of $68,581.68, $65,558.53, and $647,283.26 respectively.